Treatment Of First Patient In Systemic Clinical Trial Of AVI-4658 For Treatment Of Duchenne Muscular Dystrophy

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced treatment of the first patient in a clinical trial evaluating the systemic delivery of AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD). "We are very pleased to begin the systemic evaluation of our exon skipping drug -- AVI-4658 -- for the treatment of DMD," said Stephen Shrewsbury, M.D.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.